Maruya E, Takemoto S, Terasaki P I
Clin Transpl. 1993:511-20.
Previous studies of mismatches for a single HLA antigen in kidney transplants have not demonstrated that any single HLA antigen was more immunogenic than another. Here we show that certain mismatched antigens are "permissible" to recipients of certain types and not to others. In this retrospective study of 1,273 living-donor kidney transplants, a mismatch for 27 different, single A,B,DR antigens was evaluated with respect to recipients of various types. Various combinations of donor/recipient incompatibilities were then classified as "permissible" or immunogenic, depending upon the fate of the transplant. This list was then evaluated with 1,905 patients who received cadaver-donor transplants mismatched for a single A,B,DR antigen. Cadaver-donor kidney transplants judged to have received a permissible mismatch in the A, B, or DR loci had graft survival rates equivalent to zero-A,B,DR-mismatched grafts. Among 425 patients with one-A,B,DR-permissible mismatches, one-year graft survival was 89% with a 14.1-year half-life, compared with 966 one-A,B,DR-mismatched grafts with an 89% one-year survival and an 18-year half-life. Based upon these results, we recommend the initiation of one permissible A,B,DR-mismatched transplants for national sharing. This will result in potentially 60% of shared transplants having high long-term graft survival rates.
先前关于肾移植中单个HLA抗原错配的研究并未表明任何单个HLA抗原比其他抗原有更强的免疫原性。在此我们表明,某些错配抗原对某些类型的受者是“可允许的”,而对其他受者则不然。在这项对1273例活体供肾移植的回顾性研究中,针对27种不同的单个A、B、DR抗原错配情况,对各类受者进行了评估。然后根据移植的结局,将供体/受体不相容性的各种组合分类为“可允许的”或具有免疫原性的。接着用1905例接受单个A、B、DR抗原错配的尸体供肾移植的患者对该列表进行评估。在A、B或DR位点被判定接受了可允许错配的尸体供肾移植,其移植物存活率与零A、B、DR错配的移植物相当。在425例有一个A、B、DR可允许错配的患者中,一年移植物存活率为89%,半衰期为14.1年,相比之下,966例有一个A、B、DR错配的移植物一年存活率为89%,半衰期为18年。基于这些结果,我们建议启动一项全国性的一个可允许A、B、DR错配移植的共享计划。这将使潜在60%的共享移植具有高长期移植物存活率。